Equities

Marker Therapeutics Inc

Marker Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.14
  • Today's Change-0.150 / -3.50%
  • Shares traded12.73k
  • 1 Year change+35.82%
  • Beta1.5062
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

  • Revenue in USD (TTM)3.73m
  • Net income in USD-10.31m
  • Incorporated2018
  • Employees8.00
  • Location
    Marker Therapeutics Inc2450 HOLCOMBE BLVDSUITE BCM-A, MS: BCM251HOUSTON 77021United StatesUSA
  • Phone+1 (713) 400-6400
  • Fax+1 (302) 655-5049
  • Websitehttps://markertherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aligos Therapeutics Inc7.97m-75.74m32.57m68.00--0.9524--4.09-25.99-25.991.8910.700.0741----120,712.10-70.47-51.20-92.27-59.73-----950.61-1,399.21----0.0031--11.66--8.71---62.36--
Surrozen Inc0.00-53.45m32.60m42.00--5.38-----21.74-21.740.001.890.00----0.00-98.01---110.62-------------2.050.00---100.00---19.55------
AN2 Therapeutics Inc0.00-64.66m32.83m41.00--0.3336-----2.26-2.260.003.300.00----0.00-62.35---69.48--------------0.00-------51.33------
Impact Biomedical Inc0.00-4.25m33.34m1.00--1.43-----0.3694-0.36940.002.030.00----0.00-9.59---15.04-------------5.120.3377---100.00--38.51------
Dyadic International Inc1.80m-7.74m33.60m7.00--10.61--18.63-0.2675-0.26750.06240.10750.1662--3.55257,731.40-71.33-36.82-87.19-39.8550.0122.47-429.07-410.16----0.6324---1.0717.4830.20------
NextCure Inc0.00-61.28m36.09m82.00--0.4224-----2.20-2.200.003.050.00----0.00-47.88-22.59-51.64-23.54-------964.96----0.00------16.07---23.17--
Curis Inc10.16m-47.57m36.70m48.00------3.61-8.24-8.241.76-0.11750.1509--4.12211,687.50-70.62-37.25-90.04-41.1298.3096.05-468.18-409.44---------1.37-0.789116.34------
Marker Therapeutics Inc3.73m-10.31m36.94m8.00--3.80--9.91-1.16-1.170.41961.090.2217--1.76465,930.00-61.30-53.74-71.74-62.25-----276.53-1,438.71----0.00---5.7674.2728.97------
Nuo Therapeutics Inc1.03m-2.69m37.28m----60.77--36.24-0.0622-0.06220.02370.01320.73320.9544.06---191.94-116.16-381.40-354.8479.4870.02-261.78-854.531.39-2,383.080.00--442.12-14.990.0095------
Lumos Pharma Inc1.49m-35.75m37.70m33.00--3.45--25.37-4.43-4.430.18411.260.0382--7.4145,030.30-91.98-29.78-107.92-32.32-----2,405.72-2,937.61----0.00--34.67-30.31-9.57------
Passage Bio Inc0.00-76.57m37.86m58.00--0.418-----1.36-1.360.001.470.00----0.00-47.99-48.56-53.39-52.09------------0.00------25.02---43.53--
Elevation Oncology Inc0.00-41.95m38.42m29.00--0.554-----0.807-0.8070.001.170.00----0.00-40.67---43.53-------------375.060.309------51.93------
Serina Therapeutics Inc179.00k-18.67m38.72m4.00------216.33-9.72-9.720.0403-1.860.0156--6.2844,750.00-162.58-194.46----49.7285.80-10,438.55-2,347.36---1.82----317.65-36.69-41.49------
vTv Therapeutics Inc1.00m-20.18m40.64m16.00--2.47--40.64-6.81-6.810.27015.470.029--6.5462,500.00-73.77-111.84-170.69-------2,540.90-680.94----0.00---100.00---5.67------
DURECT Corp8.41m-15.80m41.28m47.00--8.20--4.91-0.5283-0.52830.28420.16230.21430.6827.26145,017.20-40.25-37.34-208.53-53.4480.8091.83-187.84-139.110.797-38.830.7135---55.67-10.9621.82---10.98--
Data as of Nov 08 2024. Currency figures normalised to Marker Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

9.23%Per cent of shares held by top holders
HolderShares% Held
Aisling Capital Management LPas of 30 Jun 2024314.29k3.52%
The Vanguard Group, Inc.as of 30 Jun 2024235.81k2.64%
AR Asset Management, Inc.as of 30 Jun 202470.70k0.79%
Geode Capital Management LLCas of 30 Jun 202468.24k0.77%
Renaissance Technologies LLCas of 30 Jun 202438.85k0.44%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202422.12k0.25%
SSgA Funds Management, Inc.as of 30 Jun 202420.95k0.24%
Dimensional Fund Advisors LPas of 30 Sep 202420.28k0.23%
Creative Planning LLCas of 30 Sep 202417.31k0.19%
Matrix Asset Advisors, Inc.as of 30 Sep 202415.00k0.17%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.